导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 2.96% | 599/1840 |
| 近一周 | -1.64% | 873/2029 |
| 近一月 | -2.31% | 580/2018 |
| 近一季 | -1.48% | 494/1966 |
| 近半年 | -0.70% | 568/1877 |
| 近一年 | 5.43% | 623/1753 |
| 近两年 | 37.37% | 876/1324 |
| 近三年 | 19.84% | 625/1010 |
| 成立以来 | 3.88% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-2.18% 2709/4961 |
10.68% 2400/5312 |
- - |
- - |
| 2025 | 11.24% 2757/4813 |
-3.00% 3017/3635 |
1.71% 2217/4076 |
13.37% 3004/4524 |
-0.54% 2532/4813 |
| 2024 | 13.39% 1141/3463 |
4.83% 427/2808 |
-0.32% 734/3014 |
12.17% 2401/3129 |
-3.25% 2307/3463 |
| 2023 | -7.66% 934/2656 |
6.11% 726/2280 |
-3.84% 926/2385 |
-2.93% 795/2515 |
-6.76% 1908/2655 |
| 2022 | -15.94% 441/2207 |
-12.20% 585/1919 |
6.47% 694/2016 |
-11.13% 495/2113 |
1.17% 1355/2208 |
| 2021 | 3.36% 614/1822 |
-2.34% 623/1255 |
3.81% 952/1330 |
-0.31% 487/1466 |
2.28% 637/1822 |
| 2020 | 43.20% 251/1250 |
-7.86% 575/1028 |
15.18% 512/1067 |
17.17% 113/1164 |
15.15% 232/1184 |
| 2019 | 35.29% 381/1092 |
25.18% 476/754 |
-1.77% 328/804 |
1.43% 403/850 |
8.47% 314/918 |
| 2018 | -23.47% 282/834 |
- - |
- - |
- - |
-12.24% 426/691 |
| 2017 | 18.20% 210/714 |
- - |
- - |
- - |
- - |
| 2016 | -13.01% 315/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 易方达中证国企改革(LOF)A VS. 长安沪深300非周期A(740101) |